Inovio Pharmaceuticals Inc (INO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.24 (+2.48%), Market cap $0.12B, 52-week low–high $1.05 ~ $2.87.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesio
Financial statements, price targets, institutional (13F) holdings and related news for Inovio Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Inovio Pharmaceuticals Inc trades at $1.24 (+2.48%). Real-time quotes and charts are available on BlackAll Trade.
Inovio Pharmaceuticals Inc has a market cap of about $0.12B.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human pap